

Burn Center Referral of Patients with Suspected Stevens-Johnson Syndrome And Toxic Epidermal Necrolysis



Julie A. Rizzo MD,¹ David S. Lidwell MD,¹ Leopoldo C. Cancio MD¹ ¹US Army Institute of Surgical Research, Fort Sam Houston, TX

The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.


Results

Introduction

- Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but lifethreatening desquamating skin diseases
- Often triggered by medications
- Characterized by cutaneous and mucous membrane sloughing which requires meticulous wound care often found in burn centers
- Other drug reactions and skin conditions

 83 patients referred from outside facilities for
suspicion of SJS/TEN


• 32 (38%) of patients with biopsy-confirmed SJS/TEN.



	SJS/TEN (n = 32)	Non-SJS/TEN (n = 51)	p-value
Age (mean <u>+</u> SD)	46 <u>+</u> 22	50 <u>+</u> 19	0.45
Gender (# male, %)	16 (50%)	6 (31%)	0.11
TBSA (median, IQR)	16.5 (6.9-43.8)	NM	NM
Scorten (mean <u>+</u> SD)	2 <u>+</u> 1.4	NM	NM

Demographics, NM = not measured

share similar features to SJS/TEN but do not require specialized burn care




Objectives

- Identify the incidence of patients referred for suspicion of SJS/TEN that were confirmed to have the disease
- Compare demographic characteristics and outcomes between the populations

Methods

1. Adult patients from a single center from 2016-2018 were examined in an approved Process Improvement Project



- In the SJS/TEN cohort, allopurinol and lamictal were the most common medications implicated
- In the non-SJS/TEN group, amoxicillin and Bactrim were the most common associated medications




	SJS/TEN (n = 32)	Non-SJS/TEN (n = 51)	p-value
Hospital LOS (mean <u>+</u> SD)	14.9 + 10.2	5.6 + 11	<0.001*
BICU LOS (mean <u>+</u> SD)	8.7 + 8.6	1.9 + 7	<0.001*
Ventilator days (median, IQR)	0 (0-4)	0 (0-0)	0.02*
Mortality (#, %)	4 (12.5%)	3 (5.9%)	<0.001*

Outcomes, LOS = length of stay, * statistically significant


Conclusions

- SJS/TEN best served at Burn Center
- Education and outreach can improve referral process
- Dermatology support to Burn Centers is

2. Transferred from referring facility for suspicion of SJS/TEN



Drug eruptions with associated blisters



Pustulosis or pustular drug eruption

paramount for success in managing serious skin diseases

Acknowledgements

- USAISR Burn Program for support of PI project
- Dermatology service At Brooke Army Medical Center for their continued collaboration

References

- 1. Abood GJ, Nickoloff BJ, Bamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29(1): 269-76.
- 2. Game Le H, Saeed H, Mantagos IS, et al. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey Burns 2016; 42(4): 830-5.
- 3. Cartotto R. Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Plast Surg 2017;







